Long-term safety follow-up of people treated with GF-CART01 cell therapy
Follows people with B-cell lymphoma who received GF-CART01 cells for safety up to 15 years.
Plain-language title generated from the registry record
Registry title: Long-term Study to Evaluate Safety and Persistence of GF-CART01
Key facts
- Where
- Taipei, TaiwanSee the site
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GenomeFrontier Therapeutics TW Co., Ltd.
- Trial code
- NCT06985576
- Record updated
- 11 June 2026
- Original description
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.Read full original descriptionShow less
A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Inclusion: Subjects previously enrolled in the study of GF-CART01 (Protocol No.: GF-01-01) and received GF-CART01 infusion; Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent; Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement.